Medivation (MDV) and Astellas (ALPMF.PK) enroll the first patient in a Phase II trial for...

|About: Astellas Pharma, Inc. (ALPMF)|By:, SA News Editor

Medivation (MDV) and Astellas (ALPMF.PK) enroll the first patient in a Phase II trial for enzalutamide, a treatment for triple-negative breast cancer, for which "there are no approved targeted therapies." The trial will recruit approximately 80 patients, who will take enzalutamide orally once a day. (PR)